In addition, hematopoietic tumor cells often express relatively homogeneous antigens such as CD19 in diffuse large B-cell lymphoma (DLBCL) and B-cell maturation antigen (BCMA) in MM, making it easier to apply CAR or monoclonal antibody (mAb) therapies. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.